Department of Endocrinology and Metabolism , Bursa Faculty of Medicine, Yüksek İhtisas Training and Research Hospital, University of Health Sciences, Bursa, Türkiye
Auto-generated profile, based on publicly available information
Pinar Uzgec Guller
Department of Endocrinology and Metabolism , Bursa Faculty of Medicine, Yüksek İhtisas Training and Research Hospital, University of Health Sciences, Bursa, Türkiye
Mild autonomous cortisol secretion is the most prevalent hormonal disorder identified in adrenal incidentalomas. Previous studies suggest a potential correlation between adrenal adenoma size and cortisol secretion. The aim of this study was to evaluate the associations of maximum adenoma diameter and adenoma volume with 24-hour urinary free cortisol levels and post-1-mg dexamethasone suppression test cortisol levels in patients with mild autonomous cortisol secretion. This cross-sectional observational study included 48 patients aged 18–65 years diagnosed with mild autonomous cortisol secretion. Mild autonomous cortisol secretion is defined as a serum cortisol level of ≥ 1.8 µg/dL after the 1-mg dexamethasone suppression test and a low morning adrenocorticotropic hormone. The 24-hour urinary free cortisol level was measured using liquid chromatography-tandem mass spectrometry. A radiologist blinded to hormonal test results assessed the maximum adenoma diameter and adenoma volume. The study population comprised 48 patients (women/men=43/5) with a mean age of 56.79±8.81 years. The mean maximum adenoma diameter and adenoma volume were 31.39±9.43 mm and 10.00±7.71 cm3, respectively. The mean 24-hour urinary free cortisol level was 25.34±18.21 µg/24 h. The 24-hour urinary free cortisol levels were positively correlated with both the maximum adenoma diameter and adenoma volume (ρ=0.518, p<0.001 and ρ=0.520, p<0.001, respectively), whereas no significant correlations were observed between post-1-mg dexamethasone suppression test cortisol levels and either the maximum adenoma diameter or adenoma volume. In patients with mild autonomous cortisol secretion, 24-hour urinary free cortisol levels were positively associated with maximum adenoma diameter and adenoma volume, whereas no significant associations were observed for post-1-mg dexamethasone suppression test cortisol levels. The clinical significance of these cross-sectional associations requires further investigation in large prospective longitudinal studies.
6 July 2026 in Endocrinology Research and Practice
Objective: Sarcopenia, characterized by reduced muscle mass and strength, commonly affects the elderly. This study aimed to assess sarcopenia in middle-aged, overweight patients with type 2 diabetes (T2D) and examine its relationship with glycemic control. Methods: This cross-sectional study enrolled 60 patients with T2D, including 30 individuals with poor glycemic control (PGC; glycated hemoglobin (HbA1c) >7%, mean age 54 Å} 5 years, 46.6% women) and 30 with adequate glycemic control (AGC; HbA1c ≤ 7%, mean age 54 Å} 6 years, 50% women). Sarcopenia was evaluated using handgrip strength (HGS), skeletal muscle mass index (SMMI), and the 4-meter walk test, as well as the Sarcopenia Quality of Life (SARQoL) and Pittsburgh Sleep Quality (PSQ) questionnaires. Results: Sarcopenia was diagnosed in 5 patients (16.6%), all from the PGC group. These patients had significantly lower median HGS (15.4 kg) and SMMI (7.4 kg/m2) compared to those with AGC (29.8 kg and 10.6 kg/m2; P = .021 and .006, respectively). HbA1c negatively correlated with HGS (r = −0.424; P = .001). Multivariate linear regression analysis demonstrated that higher HbA1c levels were independently associated with lower SMMI (β: −0.293; 95% CI: −0.483 to −0.102; P = .003) and lower HGS (β: −2.016; 95% CI: −2.885 to −1.147; P < .001). The SARQoL score was lower in patients with sarcopenia (P = .022), while the PSQ score was similar. Conclusion: Sarcopenia may develop in non-elderly, overweight patients with poorly controlled diabetes, negatively affecting quality of life. Early screening for sarcopenia should be considered if diabetes is uncontrolled. Cite this article as: Daloglu OO, Unal MC, Guller PU, et al. Evaluation of sarcopenia in overweight and middle-aged patients with diabetes and its association with poor glycemic control. Endocrinol Res Pract. Published online June 1, 2026. doi: 10.5152/erp.2026.25873
Background Sarcopenia is characterized by low muscle mass and strength, primarily affecting the elderly. It may also be present in patients with type 2 diabetes mellitus (T2DM), especially those with poor glycemic control. This study aimed to evaluate the frequency of sarcopenia in nonelderly and overweight patients with T2DM and its association with glycemic control. Methods A total of 60 overweight patients with T2DM (mean duration 10 ± 1.3 years) were included in the study. Patients were classified into two groups according to their HbA1c levels. There were 30 patients (mean age 54 ± 5 years; 14 [46,6%] women) in the poor glycemic control group (HbA1c > 7%) and 30 patients (mean age, 54 ± 6 years; 15[50%] women) in the adequate glycemic control group (HbA1c ≤ 7). Hand grip strength (HGS) measurements using a dynamometer, skeletal muscle mass index (SMMI) measured by bioelectrical impedance analysis, 4-m walking test, and the Sarcopenia Quality of Life (SARQoL) and Pittsburgh Sleep Quality (PSQ) questionnaires were used to assess the presence of sarcopenia and QoL in all patients. Results Five patients (16.6%) in the poor glycemic control group were diagnosed with sarcopenia based on the assessment of muscle strength and mass. Among patients with adequate glycemic control, none met the criteria for sarcopenia. The median HGS and SMMI were significantly lower in patients with sarcopenia (15.4kg and 7.4kg/m2) than in patients with adequate glycemic control (29.8 kg and 10.6kg/m2; p = 0.021 and 0.006, respectively). There was a negative correlation between HbA1c and HGS in all patients (r = 0.424; p = 0.001). Multivariate linear regression analysis revealed that an increase in HbA1c leads to a decrease in SMMI (Beta: -0.293; 95% CI: -0.483 to -0.102; p = 0.003) and HGS (Beta: -2,016; 95% CI: -2,885 to -1,147; p < 0.001). The SARQoL score was also significantly lower in patients with sarcopenia than in those with adequate glycemic control (p = 0.022), while no significant difference was found in the PSQ score. Conclusion Sarcopenia may occur in nonelderly T2DM patients with poor glycemic control, leading to decreased QoL. Screening for sarcopenia should commence at a younger age if diabetes is uncontrolled and risk factors are present.